{"a":[{"_":"Takeda gains FDA nod for first-in-class narcolepsy treatment Orzeyful","$":{"href":"/pharma/takeda-gains-fda-nod-first-class-narcolepsy-treatment-orzeyful","hreflang":"en"}}]}
RegulatoryapprovedOrzeyfulPositive
AI Analysis
Summary
Takeda received FDA approval for Orzeyful (oveporexton), the first-in-class OX2R agonist for treating narcolepsy type 1 in adults. The approval represents a significant milestone as the first medicine to address the root cause of the disorder.
Outcome Details
FDA approval for first-in-class OX2R agonist for narcolepsy type 1
Importance:8/10
Sentiment:
0.90
FDA ApprovalFirst-in-ClassNarcolepsyOX2R Agonist
Related Companies
Read the original article
Published by FiercePharma on August 6, 2026 10:36 AM